Detalles de la búsqueda
1.
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Ann Oncol
; 27(10): 1895-902, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27502710
2.
TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).
Ann Oncol
; 26(3): 561-7, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25527417
3.
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Ann Oncol
; 25(3): 682-688, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24567516
4.
Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment.
Br J Cancer
; 109(5): 1223-9, 2013 Sep 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-23942068
5.
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Br J Cancer
; 108(2): 469-76, 2013 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23169292
6.
Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
Oncology
; 84(5): 284-9, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23445718
7.
[Immunotherapy of head and neck cancer. Current developments]. / Immuntherapie von Kopf-Hals-Karzinomen. Aktuelle Entwicklungen.
HNO
; 61(7): 559-72, 2013 Jul.
Artículo
en Alemán
| MEDLINE | ID: mdl-23247754
8.
ßV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer.
Br J Cancer
; 107(5): 823-30, 2012 Aug 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-22836512
9.
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
Ann Oncol
; 23(3): 678-687, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21617019
10.
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
Ann Oncol
; 22(8): 1798-804, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21266516
11.
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck.
Cancer Chemother Pharmacol
; 76(1): 13-20, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25952795
12.
Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Cell Death Dis
; 5: e1091, 2014 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-24577089
13.
Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Eur J Cancer
; 49(13): 2877-83, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23726971
14.
[Targeted treatment of advanced lung cancer]. / Biologische Therapie beim fortgeschrittenen Lungenkarzinom.
Dtsch Med Wochenschr
; 138(40): 2034-6, 2013 Oct.
Artículo
en Alemán
| MEDLINE | ID: mdl-24065411
15.
Placebo--efficacy and adverse effects in controlled clinical trials.
Arzneimittelforschung
; 49(5): 385-93, 1999 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-10367099
Resultados
1 -
15
de 15
1
Próxima >
>>